Search Results - "Bhatia, Perminder"
-
1
Seizure Reduction With Adjunctive Cenobamate During Titration in the Phase 3 C021 Study (1815)
Published in Neurology (13-04-2021)“…Abstract only…”
Get full text
Journal Article -
2
Post hoc analysis of a phase 3, multicenter, open‐label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications
Published in Epilepsia (Copenhagen) (01-12-2021)“…Objective To report post hoc results on how adjustments to baseline antiseizure medications (ASMs) in a subset of study sites (10 US sites) from a long‐term,…”
Get full text
Journal Article -
3
Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open‐label study
Published in Epilepsia (Copenhagen) (01-12-2021)“…Objective To report long‐term post hoc efficacy and safety data from 10 US study sites from an open‐label Phase 3 study of adjunctive cenobamate (NCT02535091)…”
Get full text
Journal Article -
4
Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial
Published in Annals of internal medicine (01-12-2022)“…Parkinson disease (PD) is associated with α-synuclein (αS) aggregation within enteric neurons. ENT-01 inhibits the formation of αS aggregates and improved…”
Get full text
Journal Article -
5
Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study
Published in BMC neurology (28-03-2015)“…Eslicarbazepine acetate (ESL, Aptiom®) is a once-daily (QD) anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS). It is extensively…”
Get full text
Journal Article -
6
Dose Adjustments to Concomitant Antiseizure Medications: Post-hoc Analysis of a Phase 3, Open-Label Study of Cenobamate for Treatment of Uncontrolled Focal Seizures (1755)
Published in Neurology (13-04-2021)“…Abstract only…”
Get full text
Journal Article -
7
Efficacy of Cenobamate for Uncontrolled Focal Seizures: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study (1777)
Published in Neurology (13-04-2021)“…Abstract only…”
Get full text
Journal Article -
8
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies
Published in Parkinsonism & related disorders (01-03-2022)“…Immediate-release (IR) amantadine has been used for treatment of levodopa induced dyskinesia (LID). The immediate-release/extended-release (IR/ER) amantadine…”
Get full text
Journal Article